AdaptHealth financials
$5.67+0.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $3.24B | $3.26B | $3.20B | $2.97B | $2.47B | $1.07B | $529.6M |
| Gross profit | $609.2M | $681.1M | $624.1M | $580.1M | $456.2M | $172.1M | $88.9M |
| Gross margin | 18.8% | 20.9% | 19.5% | 19.5% | 18.5% | 16.1% | 16.8% |
| Operating income | $58.3M | $263.7M | -$598.4M | $190.4M | $225.6M | $71.3M | $29.4M |
| Net income | -$70.8M | $82.7M | -$678.9M | $63.4M | $141.8M | -$161.6M | -$21.3M |
| Net margin | −2.2% | 2.5% | −21.2% | 2.1% | 5.8% | −15.1% | −4.0% |
| Diluted EPS | $-0.52 | $0.61 | $-5.31 | $0.33 | $0.67 | $-3.08 | $-0.95 |
| EBITDA | $568.2M | $642.1M | $615.2M | $541.6M | $512.3M | $153.8M | $91.9M |
| Operating cash flow | $601.8M | $541.8M | $480.7M | $373.9M | $275.7M | $195.6M | $60.4M |
| Free cash flow | $219.4M | $235.8M | $143.2M | -$17.6M | $72.4M | $155.9M | $39.1M |
| Diluted shares | 135.1M | 135.5M | 134.4M | 139.0M | 133.0M | 52.5M | 22.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $106.1M | $109.7M | $77.1M | $46.3M | $149.6M | $100.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $1.79B | $2.02B | $2.18B | $2.19B | $2.22B | $807.0M |
| Total assets | $4.32B | $4.49B | $4.51B | $5.22B | $5.25B | $1.81B |
| Total liabilities | $2.79B | $2.91B | $3.04B | $3.06B | $3.18B | $1.53B |
| Shareholders' equity | $1.53B | $1.58B | $1.47B | $2.16B | $2.07B | $280.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology